129 related articles for article (PubMed ID: 18388921)
1. Improvement of migratory defects in a murine model of Wiskott-Aldrich syndrome gene therapy.
Blundell MP; Bouma G; Calle Y; Jones GE; Kinnon C; Thrasher AJ
Mol Ther; 2008 May; 16(5):836-44. PubMed ID: 18388921
[TBL] [Abstract][Full Text] [Related]
2. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein.
Toscano MG; Frecha C; Benabdellah K; Cobo M; Blundell M; Thrasher AJ; García-Olivares E; Molina IJ; Martin F
Hum Gene Ther; 2008 Feb; 19(2):179-97. PubMed ID: 18240968
[TBL] [Abstract][Full Text] [Related]
4. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice.
Charrier S; Stockholm D; Seye K; Opolon P; Taveau M; Gross DA; Bucher-Laurent S; Delenda C; Vainchenker W; Danos O; Galy A
Gene Ther; 2005 Apr; 12(7):597-606. PubMed ID: 15616597
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome.
Bosticardo M; Draghici E; Schena F; Sauer AV; Fontana E; Castiello MC; Catucci M; Locci M; Naldini L; Aiuti A; Roncarolo MG; Poliani PL; Traggiai E; Villa A
J Allergy Clin Immunol; 2011 Jun; 127(6):1376-84.e5. PubMed ID: 21531013
[TBL] [Abstract][Full Text] [Related]
6. B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.
Castiello MC; Scaramuzza S; Pala F; Ferrua F; Uva P; Brigida I; Sereni L; van der Burg M; Ottaviano G; Albert MH; Grazia Roncarolo M; Naldini L; Aiuti A; Villa A; Bosticardo M
J Allergy Clin Immunol; 2015 Sep; 136(3):692-702.e2. PubMed ID: 25792466
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome.
Catucci M; Prete F; Bosticardo M; Castiello MC; Draghici E; Locci M; Roncarolo MG; Aiuti A; Benvenuti F; Villa A
Gene Ther; 2012 Dec; 19(12):1150-8. PubMed ID: 22189416
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome.
Astrakhan A; Sather BD; Ryu BY; Khim S; Singh S; Humblet-Baron S; Ochs HD; Miao CH; Rawlings DJ
Blood; 2012 May; 119(19):4395-407. PubMed ID: 22431569
[TBL] [Abstract][Full Text] [Related]
9. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction.
Dupré L; Trifari S; Follenzi A; Marangoni F; Lain de Lera T; Bernad A; Martino S; Tsuchiya S; Bordignon C; Naldini L; Aiuti A; Roncarolo MG
Mol Ther; 2004 Nov; 10(5):903-15. PubMed ID: 15509508
[TBL] [Abstract][Full Text] [Related]
10. Impaired dendritic-cell homing in vivo in the absence of Wiskott-Aldrich syndrome protein.
de Noronha S; Hardy S; Sinclair J; Blundell MP; Strid J; Schulz O; Zwirner J; Jones GE; Katz DR; Kinnon C; Thrasher AJ
Blood; 2005 Feb; 105(4):1590-7. PubMed ID: 15494425
[TBL] [Abstract][Full Text] [Related]
11. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome.
Hacein-Bey Abina S; Gaspar HB; Blondeau J; Caccavelli L; Charrier S; Buckland K; Picard C; Six E; Himoudi N; Gilmour K; McNicol AM; Hara H; Xu-Bayford J; Rivat C; Touzot F; Mavilio F; Lim A; Treluyer JM; Héritier S; Lefrère F; Magalon J; Pengue-Koyi I; Honnet G; Blanche S; Sherman EA; Male F; Berry C; Malani N; Bushman FD; Fischer A; Thrasher AJ; Galy A; Cavazzana M
JAMA; 2015 Apr; 313(15):1550-63. PubMed ID: 25898053
[TBL] [Abstract][Full Text] [Related]
12. Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells.
Strom TS; Turner SJ; Andreansky S; Liu H; Doherty PC; Srivastava DK; Cunningham JM; Nienhuis AW
Blood; 2003 Nov; 102(9):3108-16. PubMed ID: 12855574
[TBL] [Abstract][Full Text] [Related]
13. Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome.
Uchiyama T; Adriani M; Jagadeesh GJ; Paine A; Candotti F
Mol Ther; 2012 Jun; 20(6):1270-9. PubMed ID: 22215016
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice.
Klein C; Nguyen D; Liu CH; Mizoguchi A; Bhan AK; Miki H; Takenawa T; Rosen FS; Alt FW; Mulligan RC; Snapper SB
Blood; 2003 Mar; 101(6):2159-66. PubMed ID: 12433691
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation.
Dupré L; Marangoni F; Scaramuzza S; Trifari S; Hernández RJ; Aiuti A; Naldini L; Roncarolo MG
Hum Gene Ther; 2006 Mar; 17(3):303-13. PubMed ID: 16544979
[TBL] [Abstract][Full Text] [Related]
16. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis.
Frecha C; Toscano MG; Costa C; Saez-Lara MJ; Cosset FL; Verhoeyen E; Martin F
Gene Ther; 2008 Jun; 15(12):930-41. PubMed ID: 18323794
[TBL] [Abstract][Full Text] [Related]
17. Expression of human Wiskott-Aldrich syndrome protein in patients' cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins.
Huang MM; Tsuboi S; Wong A; Yu XJ; Oh-Eda M; Derry JM; Francke U; Fukuda M; Weinberg KI; Kohn DB
Gene Ther; 2000 Feb; 7(4):314-20. PubMed ID: 10694812
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients.
Charrier S; Dupré L; Scaramuzza S; Jeanson-Leh L; Blundell MP; Danos O; Cattaneo F; Aiuti A; Eckenberg R; Thrasher AJ; Roncarolo MG; Galy A
Gene Ther; 2007 Mar; 14(5):415-28. PubMed ID: 17051251
[TBL] [Abstract][Full Text] [Related]
19. Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors.
Koldej RM; Carney G; Wielgosz MM; Zhou S; Zhan J; Sorrentino BP; Nienhuis AW
Hum Gene Ther Clin Dev; 2013 Jun; 24(2):77-85. PubMed ID: 23786330
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for the Wiskott-Aldrich syndrome.
Galy A; Thrasher AJ
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):545-50. PubMed ID: 21971332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
